Lördag 12 Juli | 11:24:53 Europe / Stockholm

Kalender

Est. tid*
2024-02-29 - Bokslutskommuniké 2023
2023-11-23 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-06-30 - Årsstämma
2023-05-31 - Kvartalsrapport 2023-Q1
2023-05-05 - X-dag ordinarie utdelning RLS 0.00 SEK
2023-02-28 - Bokslutskommuniké 2022
2023-02-09 - Extra Bolagsstämma 2022
2022-11-24 - Kvartalsrapport 2022-Q3
2022-08-26 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning RLS 0.00 SEK
2022-05-19 - Årsstämma
2022-05-11 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-11-12 - Kvartalsrapport 2021-Q3
2021-07-16 - Kvartalsrapport 2021-Q2
2021-06-17 - Årsstämma
2021-05-27 - X-dag ordinarie utdelning RLS 0.00 SEK
2021-05-07 - Kvartalsrapport 2021-Q1
2021-02-10 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-07-17 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning RLS 0.00 SEK
2020-05-26 - Årsstämma
2020-05-15 - Kvartalsrapport 2020-Q1
2020-02-14 - Bokslutskommuniké 2019
2019-11-15 - Kvartalsrapport 2019-Q3
2019-08-19 - Extra Bolagsstämma 2019
2019-08-15 - Kvartalsrapport 2019-Q2
2019-05-31 - X-dag ordinarie utdelning RLS 0.00 SEK
2019-05-29 - Årsstämma
2019-05-15 - Kvartalsrapport 2019-Q1
2019-02-28 - Bokslutskommuniké 2018
2018-11-30 - Kvartalsrapport 2018-Q3
2018-08-31 - Kvartalsrapport 2018-Q2
2018-06-14 - X-dag ordinarie utdelning RLS 0.00 SEK
2018-06-13 - Årsstämma
2018-05-31 - Kvartalsrapport 2018-Q1
2018-02-28 - Bokslutskommuniké 2017
2017-11-28 - Kvartalsrapport 2017-Q3
2017-11-15 - Extra Bolagsstämma 2017
2017-08-31 - Kvartalsrapport 2017-Q2
2017-06-09 - X-dag ordinarie utdelning RLS 0.00 SEK
2017-06-08 - Årsstämma
2017-05-31 - Kvartalsrapport 2017-Q1
2017-02-20 - Bokslutskommuniké 2016
2016-11-30 - Kvartalsrapport 2016-Q3
2016-08-31 - Kvartalsrapport 2016-Q2
2016-06-01 - X-dag ordinarie utdelning RLS 0.00 SEK
2016-05-31 - Årsstämma
2016-05-31 - Kvartalsrapport 2016-Q1
2016-02-29 - Bokslutskommuniké 2015
2016-01-21 - Extra Bolagsstämma 2016
2015-11-30 - Kvartalsrapport 2015-Q3
2015-08-31 - Kvartalsrapport 2015-Q2
2015-06-12 - X-dag ordinarie utdelning RLS 0.00 SEK
2015-06-11 - Årsstämma
2015-05-28 - Kvartalsrapport 2015-Q1
2015-02-27 - Bokslutskommuniké 2014
2014-11-28 - Kvartalsrapport 2014-Q3
2014-09-12 - Extra Bolagsstämma 2014
2014-08-29 - Kvartalsrapport 2014-Q2
2014-06-10 - X-dag ordinarie utdelning RLS 0.00 SEK
2014-06-09 - Årsstämma
2014-05-23 - Kvartalsrapport 2014-Q1
2014-03-05 - Bokslutskommuniké 2013
2013-11-29 - Kvartalsrapport 2013-Q3
2013-09-04 - Kvartalsrapport 2013-Q2
2013-05-31 - Kvartalsrapport 2013-Q1
2013-05-08 - Split RLS 10:1
2013-04-11 - X-dag ordinarie utdelning RLS 0.00 SEK
2013-04-10 - Årsstämma
2013-03-05 - Bokslutskommuniké 2012
2012-11-26 - Kvartalsrapport 2012-Q3
2012-08-31 - Kvartalsrapport 2012-Q2
2012-06-12 - X-dag ordinarie utdelning RLS 0.00 SEK
2012-06-11 - Årsstämma

Beskrivning

LandSverige
SektorHälsovård
IndustriMedicinteknik
RLS Global är verksamma inom bioteknik. Bolaget utvecklar biokemiska produkter och metoder för behandling av förekommande sår hos patienter. Bolagets produkter angriper skadad vävnad via den egenutvecklade teknologin som baseras på hypoklorit. Idag bedrivs forskning och utveckling inom vävnadsbaserad teknik. Bolaget har sitt huvudkontor i Göteborg.
2022-07-13 08:30:00

As of 11[th] of July 2022, ChloraSolv is available in the UK to NHS (National Health Service) organizations who purchase from NHS Supply Chain or directly from ConvaTec. ChloraSolv is available to all NHS facilities who have an account at NHS Supply Chain. It is applicable to a range of settings, including hospitals as well as primary and home care settings. ChloraSolv also can be purchased directly from ConvaTec, RLS' exclusive distribution partner for ChloraSolv in Europe.

ChloraSolv's inclusion on the NHS Supply Chain advanced wound care framework is the first step to enabling access to the UK market. In parallel, RLS and ConvaTec are working together to provide broader access to ChloraSolv across the UK, through additional routes to market.

Karin Fischer, CEO, RLS Global, says: "The UK is a strategic important market for advanced wound care and we are delighted to build on our strategic partnership with ConvaTec to bring this solution to the NHS."

RLS, together with ConvaTec, have worked to evaluate the technology and collect relevant data to secure approved access to the NHS Supply Chain. Wound debridement supports faster healing of wounds and is a fundamental part of wound management. It reduces the negative impact from hard to heal wounds on patients' quality of life. It also reduces the healthcare resources needed to support patients.

ChloraSolv is a new innovative option for wound cleansing and debridement/desloughing and reducing microbiological load. It is a unique gel application, intended for use in adult patients with chronic leg ulcers and diabetic foot ulcers in need of debridement.

ChloraSolv provides a convenient, effective and gentle option for debridement.

THIS IS CHLORASOLV:
ChloraSolv is a debriding gel, based on a unique hypochlorite technology, which is used with very good effect on leg ulcers and diabetic foot ulcers. The gel allows the gentle removal of devitalised tissue and promotes natural wound healing.[1] ChloraSolv does not damage healthy tissue and is well tolerated by the patient.

1. Eliasson B, Fagerdahl AM, Jönsson A, Apelqvist J. An open single arm multicenter pilot investigation to evaluate the debriding effect of amino acid buffered hypochlorite (ChloraSolv®) on chronic wounds covered with devitalized tissue during six weeks treatment. Journal of Wound Care (Accepted for publication).